Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections
Antimicrobial Resistance and Primary Health Care (World Health Organization, 2018).
Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318–327 (2018).
Lowy, F. D. Staphylococcus aureus infections. N. Engl. J. Med. 339, 520–532 (1998).
Solomon, S. L. & Oliver, K. B. Antibiotic resistance threats in the United States: stepping back from the brink. Am. Fam. Physician 89, 938–941 (2014).
Daum, R. S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357, 380–390 (2007).
DeLeo, F. R., Otto, M., Kreiswirth, B. N. & Chambers, H. F. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 375, 1557–1568 (2010).
DeLeo, F. R. & Chambers, H. F. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J. Clin. Invest. 119, 2464–2474 (2009).
Klein, E., Smith, D. L. & Laxminarayan, R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999–2005. Emerg. Infect. Dis. 13, 1840–1846 (2007).
Antibiotic Resistance Threats in the United States, 2019 (US Department of Health and Human Services, Centres for Disease Control and Prevention, 2019).
Piddock, L. J. The crisis of no new antibiotics—what is the way forward? Lancet Infect. Dis. 12, 249–253 (2012).
Silver, L. L. Challenges of antibacterial discovery. Clin. Microbiol Rev. 24, 71–109 (2011).
2021 Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis (World Health Organization, 2022).
Hou, X. et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 15, 41–46 (2020).
Deresinski, S. & Herrera, V. Immunotherapies for Staphylococcus aureus: current challenges and future prospects. Infect. Control Hospital Epidemiol. 31, S45–S47 (2010).
Schaffer, A. C. & Lee, J. C. Vaccination and passive immunisation against Staphylococcus aureus. Int. J. Antimicrob. Agents 32, S71–S78 (2008).
Kobayashi, S. D. & DeLeo, F. R. A MRSA-terious enemy among us: boosting MRSA vaccines. Nat. Med. 17, 168–169 (2011).
Amulic, B., Cazalet, C., Hayes, G. L., Metzler, K. D. & Zychlinsky, A. Neutrophil function: from mechanisms to disease. Annu. Rev. Immunol. 30, 459–489 (2012).
Xue, J. et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. Nat. Nanotechnol. 12, 692–700 (2017).
Gonzalez-Barca, E., Carratala, J., Mykietiuk, A., Fernandez-Sevilla, A. & Gudiol, F. Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer. Eur. J. Clin. Microbiol. Infect. Dis. 20, 117–119 (2001).
Lakshman, R. & Finn, A. Neutrophil disorders and their management. J. Clin. Pathol. 54, 7–19 (2001).
Bouma, G., Ancliff, P. J., Thrasher, A. J. & Burns, S. O. Recent advances in the understanding of genetic defects of neutrophil number and function. Br. J. Haematol. 151, 312–326 (2010).
Andrews, T. & Sullivan, K. E. Infections in patients with inherited defects in phagocytic function. Clin. Microbiol. Rev. 16, 597–621 (2003).
Antibacterial Products in Clinical Development for Priority Pathogens (World Health Organization, 2021); https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antibacterial-products-in-clinical-development-for-priority-pathogens
Liu, C.-I. et al. A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence. Science 319, 1391–1394 (2008).
Liu, G. Y. et al. Staphylococcus aureus golden pigment impairs neutrophil killing and promotes virulence through its antioxidant activity. J. Exp. Med. 202, 209–215 (2005).
Shatalin, K., Shatalina, E., Mironov, A. & Nudler, E. H2S: a universal defense against antibiotics in bacteria. Science 334, 986–990 (2011).
Shatalin, K. et al. Inhibitors of bacterial H2S biogenesis targeting antibiotic resistance and tolerance. Science 372, 1169–1175 (2021).
Guerra, F. E., Borgogna, T. R., Patel, D. M., Sward, E. W. & Voyich, J. M. Epic immune battles of history: neutrophils vs. Staphylococcus aureus. Front. Cell. Infect. Microbiol. 7, 286 (2017).
de Haas, C. J. et al. Chemotaxis inhibitory protein of Staphylococcus aureus, a bacterial antiinflammatory agent. J. Exp. Med. 199, 687–695 (2004).
Rooijakkers, S. H. et al. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases. Nat. Immunol. 6, 920–927 (2005).
Simmen, H.-P. & Blaser, J. Analysis of pH and pO2 in abscesses, peritoneal fluid, and drainage fluid in the presence or absence of bacterial infection during and after abdominal surgery. Am. J. Surg. 166, 24–27 (1993).
Bartlett, J. G. & Finegold, S. M. Anaerobic infections of the lung and pleural space. Am. Rev. Respir. Dis. 110, 56–77 (1974).
McGovern, N. N. et al. Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophils. J. Immunol. 186, 453–463 (2011).
Chen, F. et al. Small-molecule targeting of a diapophytoene desaturase inhibits S. aureus virulence. Nat. Chem. Biol. 12, 174–179 (2016).
Krute, C. N., Ridder, M. J., Seawell, N. A. & Bose, J. L. Inactivation of the exogenous fatty acid utilization pathway leads to increased resistance to unsaturated fatty acids in Staphylococcus aureus. Microbiology 165, 197 (2019).
Tiwari, K. B., Gatto, C. & Wilkinson, B. J. Plasticity of coagulase-negative staphylococcal membrane fatty acid composition and implications for responses to antimicrobial agents. Antibiotics 9, 214 (2020).
Beavers, W. N. et al. Arachidonic acid kills Staphylococcus aureus through a lipid peroxidation mechanism. mBio https://doi.org/10.1128/mbio.01333-19 (2019).
Reeder, B. J. & Wilson, M. T. Hemoglobin and myoglobin associated oxidative stress: from molecular mechanisms to disease states. Curr. Med. Chem. 12, 2741–2751 (2005).
Alayash, A. I. Oxygen therapeutics: can we tame haemoglobin? Nat. Rev. Drug Discov. 3, 152–159 (2004).
Vitvitsky, V. et al. Structural and mechanistic insights into hemoglobin-catalyzed hydrogen sulfide oxidation and the fate of polysulfide products. J. Biol. Chem. 292, 5584–5592 (2017).
Vitvitsky, V., Yadav, P. K., Kurthen, A. & Banerjee, R. Sulfide oxidation by a noncanonical pathway in red blood cells generates thiosulfate and polysulfides. J. Biol. Chem. 290, 8310–8320 (2015).
Boutaud, O. et al. Acetaminophen inhibits hemoprotein-catalyzed lipid peroxidation and attenuates rhabdomyolysis-induced renal failure. Proc. Natl Acad. Sci. USA 107, 2699–2704 (2010).
Alayash, A. I. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nat. Biotechnol. 17, 545–549 (1999).
Ayala, A., Muñoz, M. F. & Argüelles, S. Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid. Med. Cell. Longev. 2014, 360438 (2014).
Katikaneni, A. et al. Lipid peroxidation regulates long-range wound detection through 5-lipoxygenase in zebrafish. Nat. Cell Biol. 22, 1049–1055 (2020).
Rummer, J. L., McKenzie, D. J., Innocenti, A., Supuran, C. T. & Brauner, C. J. Root effect hemoglobin may have evolved to enhance general tissue oxygen delivery. Science 340, 1327–1329 (2013).
Hochmuth, R., Evans, C., Wiles, H. & McCown, J. Mechanical measurement of red cell membrane thickness. Science 220, 101–102 (1983).
Hu, C.-M. J. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980–10985 (2011).
Hu, C. M. et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature 526, 118–121 (2015).
Zhang, Q. et al. Neutrophil membrane-coated nanoparticles inhibit synovial inflammation and alleviate joint damage in inflammatory arthritis. Nat. Nanotechnol. 13, 1182–1190 (2018).
Su, J. et al. Bioinspired nanoparticles with NIR‐controlled drug release for synergetic chemophotothermal therapy of metastatic breast cancer. Adv. Funct. Mater. 26, 7495–7506 (2016).
Lin, A. et al. Bacteria-responsive biomimetic selenium nanosystem for multidrug-resistant bacterial infection detection and inhibition. ACS Nano 13, 13965–13984 (2019).
Berube, B. J. & Bubeck Wardenburg, J. Staphylococcus aureus α-toxin: nearly a century of intrigue. Toxins 5, 1140–1166 (2013).
Clauditz, A., Resch, A., Wieland, K.-P., Peschel, A. & Götz, F. Staphyloxanthin plays a role in the fitness of Staphylococcus aureus and its ability to cope with oxidative stress. Infect. Immun. 74, 4950–4953 (2006).
Ren, M. et al. A TICT-based fluorescent probe for rapid and specific detection of hydrogen sulfide and its bio-imaging applications. Chem. Commun. 52, 6415–6418 (2016).
Balaban, N. Q. et al. Definitions and guidelines for research on antibiotic persistence. Nat. Rev. Microbiol. 17, 441–448 (2019).
Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417–433 (2010).
Levin, B. R. & Rozen, D. E. Non-inherited antibiotic resistance. Nat. Rev. Microbiol. 4, 556–562 (2006).
Keren, I., Kaldalu, N., Spoering, A., Wang, Y. & Lewis, K. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230, 13–18 (2004).
Allison, K. R., Brynildsen, M. P. & Collins, J. J. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473, 216–220 (2011).
Conlon, B. P. et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503, 365–370 (2013).
Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318–1322 (1999).
Schaible, B., Taylor, C. T. & Schaffer, K. Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. Antimicrob. Agents Chemother. 56, 2114–2118 (2012).
Meredith, H. R., Srimani, J. K., Lee, A. J., Lopatkin, A. J. & You, L. Collective antibiotic tolerance: mechanisms, dynamics and intervention. Nat. Chem. Biol. 11, 182–188 (2015).
Everse, J. & Hsia, N. The toxicities of native and modified hemoglobins. Free Radic. Biol. Med. 22, 1075–1099 (1997).
Kolaczkowska, E. & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159–175 (2013).
Payne, J. A. et al. Antibiotic-chemoattractants enhance neutrophil clearance of Staphylococcus aureus. Nat. Commun. 12, 6157 (2021).
Quinn, M. T., Ammons, M. C. B. & DeLeo, F. R. The expanding role of NADPH oxidases in health and disease: no longer just agents of death and destruction. Clin. Sci. 111, 1–20 (2006).
Luo, B. et al. Phagocyte respiratory burst activates macrophage erythropoietin signalling to promote acute inflammation resolution. Nat. Commun. 7, 12177 (2016).
Gao, W., Thamphiwatana, S., Angsantikul, P. & Zhang, L. Nanoparticle approaches against bacterial infections. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 6, 532–547 (2014).
Azzopardi, E. A., Ferguson, E. L. & Thomas, D. W. The enhanced permeability retention effect: a new paradigm for drug targeting in infection. J. Antimicrob. Chemother. 68, 257–274 (2013).
Ye, M. et al. A dual‐responsive antibiotic‐loaded nanoparticle specifically binds pathogens and overcomes antimicrobial‐resistant infections. Adv. Mater. 33, e2006772 (2021).
Thorn, C. R., Thomas, N., Boyd, B. J. & Prestidge, C. A. Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy. Drug Deliv. Transl. Res. 11, 1598–1624 (2021).
Lakshminarayanan, R., Ye, E., Young, D. J., Li, Z. & Loh, X. J. Recent advances in the development of antimicrobial nanoparticles for combating resistant pathogens. Adv. Healthc. Mater. 7, 1701400 (2018).
Wang, L., Hu, C. & Shao, L. The antimicrobial activity of nanoparticles: present situation and prospects for the future. Int. J. Nanomed. 12, 1227 (2017).
Fenaroli, F. et al. Enhanced permeability and retention-like extravasation of nanoparticles from the vasculature into tuberculosis granulomas in zebrafish and mouse models. ACS Nano 12, 8646–8661 (2018).
Repenko, T. et al. Bio-degradable highly fluorescent conjugated polymer nanoparticles for bio-medical imaging applications. Nat. Commun. 8, 470 (2017).
Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519–531 (2011).
Selsted, M. E. & Ouellette, A. J. Mammalian defensins in the antimicrobial immune response. Nat. Immunol. 6, 551–557 (2005).
Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303–6308 (2009).
Klebanoff, S. J. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77, 598–625 (2005).
Foster, T. J. Immune evasion by staphylococci. Nat. Rev. Microbiol. 3, 948–958 (2005).
Howden, B. P. et al. Staphylococcus aureus host interactions and adaptation. Nat. Rev. Microbiol. 21, 380–395 (2023).
Thammavongsa, V., Missiakas, D. M. & Schneewind, O. Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science 342, 863–866 (2013).
Myles, I. A. et al. Signaling via the IL-20 receptor inhibits cutaneous production of IL-1β and IL-17A to promote infection with methicillin-resistant Staphylococcus aureus. Nat. Immunol. 14, 804–811 (2013).
Schmaler, M., Jann, N. J., Ferracin, F. & Landmann, R. T and B cells are not required for clearing Staphylococcus aureus in systemic infection despite a strong TLR2–MyD88-dependent T cell activation. J. Immunol. 186, 443–452 (2011).
Ren, X., Zou, L. & Holmgren, A. Targeting bacterial antioxidant systems for antibiotics development. Curr. Med. Chem. 27, 1922–1939 (2020).
Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl Acad. Sci. USA 112, 4453–4458 (2015).
Lu, J. et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. FASEB J. 27, 1394–1403 (2013).
Luk, B. T. et al. Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles. Nanoscale 6, 2730–2737 (2014).
Lv, W. et al. Bioengineered boronic ester modified dextran polymer nanoparticles as reactive oxygen species responsive nanocarrier for ischemic stroke treatment. ACS Nano 12, 5417–5426 (2018).
Hall, G. S. Bailey & Scott’s Diagnostic Microbiology, 13th edn. Laboratory Medicine 44, e138–e139 (2013).
Peng, B. et al. Fluorescent probes based on nucleophilic substitution–cyclization for hydrogen sulfide detection and bioimaging. Chem.–A Eur. J. 20, 1010–1016 (2014).
Lee, A. S. et al. Methicillin-resistant Staphylococcus aureus. Nat. Rev. Dis. Prim. 4, 1–23 (2018).
Kim, W. et al. A new class of synthetic retinoid antibiotics effective against bacterial persisters. Nature 556, 103–107 (2018).
Merritt, J. H., Kadouri, D. E. & O’Toole, G. A. Growing and analyzing static biofilms. Curr. Protoc. Microbiol. 22, 1B.1.1–1B.1.18 (2011).
Lu, M. et al. Bacteria-specific phototoxic reactions triggered by blue light and phytochemical carvacrol. Sci. Transl. Med. 13, eaba3571 (2021).
Drummen, G. P., van Liebergen, L. C., den Kamp, J. A. O. & Post, J. A. C11-BODIPY581/591, an oxidation-sensitive fluorescent lipid peroxidation probe: (micro) spectroscopic characterization and validation of methodology. Free Radic. Biol. Med. 33, 473–490 (2002).
Monogue, M. L., Thabit, A. K., Hamada, Y. & Nicolau, D. P. Antibacterial efficacy of eravacycline in vivo against Gram-positive and Gram-negative organisms. Antimicrob. Agents Chemother. 60, 5001–5005 (2016).
Harrison, E. M. et al. Genomic identification of cryptic susceptibility to penicillins and β-lactamase inhibitors in methicillin-resistant Staphylococcus aureus. Nat. Microbiol. 4, 1680–1691 (2019).
Kumar, A., Accorsi, A., Rhee, Y. & Girgenrath, M. Do’s and don’ts in the preparation of muscle cryosections for histological analysis. J. Vis. Exp. 15, e52793 (2015).
Ye, M. et al. pH‐responsive polymer–drug conjugate: an effective strategy to combat the antimicrobial resistance. Adv. Funct. Mater. 30, 2002655 (2020).
Inoshima, I. et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat. Med. 17, 1310–1314 (2011).
Hua, L. et al. Assessment of an anti-α-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob. Agents Chemother. 58, 1108–1117 (2014).
Mortin, L. I. et al. Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria. Antimicrob. Agents Chemother. 51, 1787–1794 (2007).
Surewaard, B. G. et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo. J. Exp. Med. 213, 1141–1151 (2016).
Wozniak, J. M. et al. Mortality risk profiling of Staphylococcus aureus bacteremia by multi-omic serum analysis reveals early predictive and pathogenic signatures. Cell 182, 1311–1327. e1314 (2020).